PGEN
NASDAQ · Biotechnology
Precigen Inc
$4.22
-0.84 (-16.52%)
Performance
1D
-5.59%
1W
-17.90%
1M
-44.47%
3M
-39.71%
6M
+0.48%
1Y
+8.21%
YTD
-1.40%
Open$4.71
Previous Close$5.06
Day High$4.74
Day Low$3.92
52W High$8.98
52W Low$3.04
Volume—
Avg Volume9.77M
Market Cap1.53B
P/E Ratio—
EPS$-0.52
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$6.98
Below
SMA 200
$5.28
Below
RSI (14)
28.9
Oversold
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
10 analysts
Price Target
+1,619.7% upside
Current
$4.22
$4.22
Target
$72.57
$72.57
$43.64
$72.57 avg
$99.14
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 11.23M | 15.79M | 411.38M |
| Net Income | -291,130,840 | -368,312,842 | -34,816,902 |
| Profit Margin | -2,588.2% | -2,458.8% | -8.5% |
| EBITDA | -124,661,295 | -166,472,069 | -49,679,638 |
| Free Cash Flow | — | — | -21,385,787 |
| Rev Growth | -28.9% | -28.9% | +17.8% |
| Debt/Equity | 4.46 | 4.46 | 0.95 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |